1. Anderson C, Cone M, Walker S. Bridging studies in Asia and the impact of the ICH E5 guideline. Drug Inf J. 2003;37(November):107S–116S.
2. Denker AE, et al. Sources of potential ethnic differences in pharmacokinetics. Drug Inf J. 2003;37(November):99S–106S.
3. Kuo WH. Understanding race at the frontier of pharmaceutical regulation: an analysis of the racial difference debate at the ICH. J Law Med Ethics. 2008;36(3):498–505.
4. Question 26 and its answer in the Ministry of Health. Labor, and Wealth’s guidance on the E5 guideline. In Yakugyoziho. ed. Kawarusinyak-ukaihatu no kokusaisenryuku: ICH E5 gaidnrain no inpakuta [Changing global strategies for new drug development: the impact of the ICH E5 guideline]. Tokyo: Yakugyozihosha.
5. Mori K. Recent situation of clinical trial consultation in Japan—especially consultation about bridging study. Presentation at the 2001 APEC Meeting for Pharmaceutical Regulatory Network. Taipei, Taiwan, May 25–26.